ACT-CTU Clinical Trial Rounds - December 10, 2025

Value of the Information & Strength of the Argument

The presentation provides valuable insights into the rationale for using human challenge models, backed by specific examples and data. Dr. Ward argues convincingly for the need to move beyond animal models, citing differences in immune system structure and the poor predictive value of animal data. He supports his arguments with references to published studies and his own research. The ethical discussion is balanced, acknowledging risks while presenting safety data. The argumentation is solid, though some points are based on personal experience and opinion rather than systematic review.

Scientific Rigor, Source Quality, Title Accuracy

The speaker is a highly credible expert with extensive experience. He cites specific studies (e.g., the 2013 transcriptional study) and WHO guidelines. He also discloses his competing interests, which is good practice. The title accurately reflects the content. However, the talk is a lecture, so not all claims are formally referenced, and the speaker’s own research is presented with potential bias. The Q&A session adds to the rigor by addressing potential limitations.

The title accurately reflects the content: a clinical trial rounds presentation on controlled human infection models.

8/10

The presentation is given by a highly qualified expert (Professor Emeritus at McGill, with extensive experience in infectious diseases and vaccine development). The content is based on peer-reviewed literature, WHO guidelines, and the presenter's own research. The speaker discloses competing interests. The talk includes specific data (e.g., serious adverse event rates) and references to published studies. However, as it is a lecture, some claims are not fully referenced in the video, and the speaker's own research is presented with potential bias.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 02:00Introduction of Dr. Brian Ward by the host.
• 05:00Dr. Ward discusses the costs of clinical trial phases and the need for industry partners.
• 10:00Explanation of the limitations of animal models, citing a 2013 study on transcriptional responses.
• 15:00Description of the planned influenza challenge study in Canada.
• 20:00Discussion of the use of tonsillar organoids and lymph node aspirates for vaccine research.
• 25:00Overview of the safety data of CHIMs, including serious adverse event rates.
• 30:00Historical examples of intentional infection, such as variolation and malaria therapy.
• 35:00Discussion of the ethical guidelines from WHO for CHIMs.
• 40:00Examples of CHIM studies for various pathogens, including malaria and influenza.
• 45:00Q&A session addressing sampling bias and limitations of CHIMs.

• WHO guidance on controlled human infection model studies — Referenced as the WHO guidance for ethical conduct of CHIM studies.
• Seok et al. 2013, PNAS, Genomic responses in mouse models poorly mimic human inflammatory diseases — Cited as the study showing poor correlation between mouse and human transcriptional responses.
• Systematic review of human challenge studies designs and safety (1980-2020) — Referenced for safety data on CHIMs.

• WHO guidance on controlled human infection model studies — The WHO guidance supports the ethical framework discussed in the talk.
• Seok et al. 2013, PNAS — This study supports the argument that animal models often fail to predict human responses.

• Concerns about the generalizability of CHIM results — The Q&A session raises the issue of sampling bias, as CHIMs typically enroll healthy young adults, which may not represent the general population.